Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes

    loading  Checking for direct PDF access through Ovid

Abstract

To study whether an in-vitro model for three different genotypes of human CYP2C9*3 polymorphism would be useful for predicting the in-vivo kinetics of (S)-warfarin in patients with the corresponding genotypes, the intrinsic clearance (CIint or Vmax/Km) for (S)-warfarin 7-hydroxylation obtained from recombinant human CYP2C9*1 [wild-type (wt)] and CYP2C9*3 (Leu359/Leu) expressed in yeast and the mixture of equal amounts of these were compared with the in-vivo unbound oral Cl (CIpo,u) of (S)-warfarin obtained from 47 Japanese cardiac patients with the corresponding CYP2C9 genotypes. The in-vitro study revealed that the recombinant CYP2C9*1 (wt/wt), 2C9*3 (Leu359/Leu) and their mixture (IIe359/Leu) possessed a meanKm of 2.6, 10.4 and 6.6 μM and Vmax of 280, 67 and 246 pmol/min/nmol P450, respectively. Thus, the mean in-vitro Cljnt obtained from recombinant CYP2C9*3 (Leu359/Leu) and the mixture (Ile359/Leu) of 2C9*3 and 2C9*1 were 94% and 65% lower than that obtained from CYP2C9*1 (wt/wt) (6.7 versus 38 versus 108 nil/imn/uinol P450, respectively). The in-vivo study showed that the median CIpo,u for (S)-warfarin obtained from patients with homozygous (Leu359/Leu, n=1) and heterozygous (Ile359/Leu, n - 4) CYP2C9*3 mutations were reduced by 90% (62 ml/min) and 66% (212 ml/min, P<0.05) compared with that obtained from those with homozygous 2C9*1 (625 ml/min, n=42). Consequently, there was a significant correlation (r=0.99, P<0.05) between the in-vitro Clint for (S)-warfarin 7-hydroxylation and the in-vivo CIpo,u for (S)-warfarin in relation to the CYP2C9*3 polymorphism. In conclusion, the in-vitro model for human CYP2C9*3 polymorphism using recombinant cytochrome P450 proteins would serve as a useful means for predicting changes in in-vivo kinetics for (S)-warfarin and possibly other CYP2C9 substrates in relation to CYP2C9*3 polymorphism.

Related Topics

    loading  Loading Related Articles